



Study Title:	Treatment Trial for Large B-Cell Lymphoma Patients That Have Achieved Complete Response Following Chemotherapy
Scientific Title:	Novartis - Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Department and/or Specialty:	Oncology-Hematology-lymphoma
Investigator:	Michael Thompson, MD, PhD
Contact Information:	Chanda Miller 262-928-5539

Summary

Phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximab-chemotherapy



PROHEALTH CARE
RESEARCH INSTITUTE